| Targets of T Cell Responses to SARS-CoV-2 Coronavirus
in Humans with COVID-19 Disease and Unexposed Individuals146
|
Cell (May 20, 2020) |
identified and quantified circulating SARS-CoV-2-specific CD8+ and CD4+ T cells in ∼70% and 100% of COVID-19 convalescent
patients, respectively. CD4+ T cell responses to the viral S protein were
robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. |
| Development of an inactivated
vaccine candidate for SARS-CoV-2147
|
Science (July
3, 2020) |
inactivated SARS-CoV-2 virus vaccine, PiCoVacc, against SARS-CoV-2 strain in mice, rats, and nonhuman primates |
| Self-amplifying RNA SARS-CoV-2 lipid
nanoparticle vaccine candidate induces high neutralizing antibody
titers in mice148
|
Nature Communications (July 9, 2020) |
mRNA vaccine encoding the SARS-CoV-2 S protein encapsulated in a lipid
nanoparticle |
| An mRNA vaccine against SARS-CoV-2 - preliminary report57
|
The New
England Journal of Medicine (July 14, 2020) |
results from a Phase 1 clinical trial
for Moderna vaccine, mRNA-1273, in three different doses |
| Immunogenicity and safety of a recombinant adenovirus
type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or
older: a randomized, double-blind, placebo-controlled, Phase 2 trial149
|
Lancet (July
20, 2020) |
single-dose, nonreplicating adenovirus vector
vaccine expressing the full-length SAR-CoV-2 S protein gene |
| Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques129
|
Nature (July 30, 2020) |
preclinical study on immunogenicity and protective efficacy of a
single dose of adenovirus serotype 26 (Ad26) vector-based vaccine
expressing the SARS-CoV-2 S protein in nonhuman primates |
| A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity150
|
Nature (July 29, 2020) |
recombinant
protein subunit vaccine tested in nonhuman primates |
| A single immunization with nucleoside-modified mRNA vaccines
elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice151
|
Immunity (July 30, 2020) |
two mRNA-LNP vaccines encoding: (1)
the full-length SARS-CoV-2 S protein with deleted furin cleavage site and (2)
receptor-binding site of the S protein, respectively |
| A universal design of beta-coronavirus
vaccines against COVID-19, MERS, and SARS152
|
Cell (August 6, 2020) |
structure-guided design of protein subunit vaccine composed of tandem
repeat single-chain dimer of the RBD of coronavirus |
| A single dose of an adenovirus-vectored vaccine provides protection
against SARS-CoV-2 challenge153
|
Nature
Communications (August 14, 2020) |
nonreplicating
human adenovirus vector-based vaccine encoding SARS-CoV-2 S protein (Ad5-nCoV) tested in mice |
| Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters132
|
Nature Medicine (September 3, 2020) |
adenovirus vector-based vaccine
expressing a stabilized SARS-CoV-2 S protein |
| Safety and immunogenicity of two RNA-based
Covid-19 vaccine candidates58
|
The New England Journal of
Medicine (October 14, 2020) |
nucleotide-modified
(1-methylpseudouridine) mRNA vaccine by Pfizer/BioNTech encoding the SARS-CoV-2 S protein |
| A platform incorporating trimeric antigens
into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing
responses than spike alone112
|
Nature (October 23,
2020) |
two nanoparticle platforms, lumazine synthase
and ferritin, for the display of trimeric viral protein immunogens
using the SpyTag:SpyCatcher system with added N-linked
glycosylation sites to nanoparticle monomers to allow the production
of the specified nanoparticles in mammalian cell culture |
| Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity154
|
Cell (November
12, 2020) |
a combined examination of SARS-CoV-2-specific CD4+ and CD8+ T cell and
neutralizing antibody responses in acute and convalescent subjects |
| Eliciting B cell immunity
against infectious diseases using nanovaccines155
|
Nature
Nanotechnology (November 16, 2020) |
review of
nanovaccine transport, localization, and antibody responses as well
as its promises and challenges |
| Safety and
efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized
controlled trials in Brazil, South Africa, and the UK156
|
Lancet (December 8, 2020) |
evaluated the safety
and efficacy of the adenovirus-vectored vaccine (AZD1222) expressing
the SARS-CoV-2 S protein in a pooled interim analysis of four trials |
| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine62
|
The New England Journal of Medicine (December 10,
2020) |
result from a multinational, randomized, placebo-controlled,
observer-blinded clinical trial for a two-dose regimen of BNT162b2 |
| Safety and efficacy of the mRNA-1273 SARS-CoV-2 vaccine61
|
The New England Journal of Medicine (December 30,
2020) |
result from the Phase 3 randomized, observed-blinded, placebo-controlled clinical trial
of mRNA-1273 conducted in the U.S. |
| Immunological
memory to SARS-CoV-2 assessed for up
to 8 months after infection157
|
Science (February
5, 2021) |
assessed multiple compartments of circulating
immune memory to SARS-CoV-2 in hundreds
of COVID-19 cases |
| Safety and immunogenicity
of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19
in healthy adults: a phase 1, randomized,
double-blind, placebo-controlled trial158
|
Lancet (February 2021) |
reported vaccine SCB-2019 developed by Clover Biopharmaceuticals
which contains a stabilized trimeric form of the S protein combined
with two different adjuvants |
| Antibody Resistance
of SARS-CoV-2 Variants B.1.351 and
B.1.1.7141
|
Nature (March 8, 2021) |
tested the effectiveness of neutralizing
antibodies and mRNA vaccines mRNA-1273 and BNT162b2 against two SARS-CoV-2 variants |
